Last reviewed 2018-03-08 · How we verify
Home › Trials › NCT03245528 Expanded Access for LJPC-501
NCT03245528
APPROVED_FOR_MARKETING
The primary objective of the study is to provide access to LJPC-501 for distributive shock patients who remain hypotensive despite receiving fluid and vasopressor therapy.
Details
Lead sponsor La Jolla Pharmaceutical Company Status APPROVED_FOR_MARKETING
Conditions Catecholamine Resistant Hypotension (CRH) Distributive Shock High Output Shock Sepsis Vasodilatory Shock Interventions
Source: ClinicalTrials.gov. Drug Landscape entry: https://druglandscape.com/trial/NCT03245528.
See also: ClinicalTrials.gov record .
Not medical advice. Information on this page is collated from primary regulatory and clinical-trial sources for research purposes. It is not a substitute for consultation with a licensed healthcare professional. See our editorial policy for sourcing and methodology.